GLP-1 Supplements: Do Any of Them Actually Work?

In two years, “GLP-1” has gone from a hormone almost nobody outside endocrinology had heard of to a phrase printed on gummies, patches, drink powders, probiotic capsules and sublingual drops. One market research firm valued the global GLP-1 supplement market at $2 billion in 2025 and projects $5.53 billion by 2034 [1]. A separate estimate put GLP-1 “companion products” at $5.2 billion in 2026 [2]. Both are vendor-published estimates, but the direction is not in dispute.

So: is any of it real?

The short answer is that the category divides cleanly in two, and the answer is different for each half.

What are the two kinds of GLP-1 supplement?

Regulatory specialists in the supplement industry describe the split plainly. GLP-1 products in the supplement aisle fall into either products that provide nutritional support for people already taking a GLP-1 drug, or products that claim to mimic the pharmaceutical effect of those drugs [3].

That distinction does almost all the work in this article.

The first group has a defensible rationale. If a drug suppresses your appetite by 20 to 30 percent, protein intake, fiber, hydration and micronutrients become genuinely harder to hit, and constipation is common. In 2025, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society published a joint advisory on nutritional priorities to support GLP-1 therapy for obesity [4]. A 2025 narrative review on supplements during GLP-1 treatment concluded that fiber supplements may be beneficial for people on GLP-1 drugs on a case-by-case basis, particularly for constipation [4].

The second group is the one this article is mostly about, and its evidence base is thin.

What is actually inside a “GLP-1 booster”?

Pull the labels and the same short list keeps appearing: prebiotic fiber or resistant starch, probiotics (usually Akkermansia muciniphila), berberine, chromium picolinate, green tea extract, resveratrol, and botanicals such as saffron extract, 5-HTP, bupleurum root or cayenne [5].

Published 2026 label comparisons are instructive. One widely sold GLP-1 booster lists berberine at 200 mg per serving alongside chromium picolinate, 5-HTP, saffron extract and bupleurum root, with no finished-product trial and berberine at what the analysis called a sub-clinical dose [6]. The berberine trials people cite used 500 mg three times daily, or 1,500 mg. Another booster lists Akkermansia muciniphila, a proprietary probiotic blend and cayenne pepper, with the underlying Akkermansia mechanism studied only in mice and in vitro [6].

This is the pattern worth learning: the marketing page cites a study, the label contains the ingredient from that study, and the amount on the label is a fraction of the amount in the study.

What does the ingredient-by-ingredient evidence say?

Berberine. Pooled analyses of randomized trials find between no significant weight change and about 0.84 kg, roughly under two pounds, over 8 to 18 weeks. Effects on blood sugar and lipids are better supported than effects on weight. Berberine also inhibits CYP2D6, CYP3A4 and CYP2C9, which means real potential to raise levels of other medications [7].

Chromium picolinate. Meta-analyses going back to 2003 find a small, statistically detectable effect. A 2019 meta-analysis of 21 trials (n=1,316, 9-24 weeks, 200-1,000 mcg/day) found 0.75 kg more weight loss than placebo, a 0.40 kg/m² BMI reduction and a 0.68% body fat reduction, with no significant waist effect [8]. An earlier 11-study analysis found a mean difference of −0.50 kg. A 2023 dose-response meta-analysis in people with type 2 diabetes found no significant effect on body weight, BMI, waist circumference or fat mass at all. So: roughly one to two pounds, at best, over several months.

Akkermansia muciniphila. This is the strongest ingredient in the category, and it deserves a fair hearing. In a 2019 Nature Medicine proof-of-concept trial (n=32 completers, 3 months), pasteurized A. muciniphila was safe and well tolerated and improved insulin sensitivity by 28.6%, reduced insulinemia by 34.1% and lowered total cholesterol by 8.7%. Body weight fell by 2.27 kg versus placebo, but at P=0.091 that did not reach statistical significance [9].

A newer and stronger trial was published in Nature Medicine on May 12, 2026. Ninety adults with overweight or obesity first completed an 8-week low-energy diet to lose at least 8% of body weight, then entered a 24-week maintenance phase on either pasteurized A. muciniphila MucT or placebo. The supplement group regained 1.2 kg against 3.2 kg on placebo (P=0.012), a difference of about 2 kg, and preserved insulin sensitivity better. The benefit appeared largest in people who started with low Akkermansia levels and in those with prediabetes [10]. Independent experts called the design sound and the primary outcome positive, while noting it is a maintenance trial, not a weight-loss trial, and that hunger hormones including GLP-1 itself barely moved [25].

One sourcing note worth stating plainly, because it is the kind of gap this article exists to flag: the trial was funded by the ingredient’s manufacturer, and the manufacturer’s own press materials described the benefit as “about three kilograms.” The journal’s numbers are 1.2 kg versus 3.2 kg, a roughly 2 kg difference. We use the published figures.

So: about 2 kg of avoided regain over six months, against the 14.9% mean weight loss semaglutide produced over 68 weeks in STEP 1, roughly 15 kg [30]. Different scale, different claim.

Resistant starch and prebiotic fiber. Resistant starch does raise GLP-1 and PYY through colonic fermentation into short-chain fatty acids; that mechanism is well documented in animal studies going back to 2008. Human results are more mixed, and at least one controlled feeding study found a psyllium-enriched meal actually suppressed the postprandial GLP-1 rise while prolonging PYY. Fiber is good for you. It is not a drug.

Green tea extract, garcinia cambogia, CLA, raspberry ketone. These are legacy diet-pill ingredients repackaged under new branding. They sit inside the corpus reviewed by The Obesity Society and are not supported by higher-quality trials. Concentrated green tea extract adds a documented idiosyncratic liver-injury signal that brewed tea does not carry.

Yerba mate. Called “nature’s Ozempic” on TikTok, largely on the strength of a 2011 mouse study showing mate tea promoted satiety with GLP-1 involvement [11]. The main human study often cited is a 2001 trial of a three-herb combination (yerba mate, guarana and damiana), not mate alone. Reported human weight effects are typically under two pounds when combined with calorie restriction.

What is the honest summary across the whole category?

The best single number comes from The Obesity Society. Researchers screened 20,504 citations, reviewed 1,743 full-text articles and analyzed 315 randomized controlled trials of 14 purported dietary supplements, therapies or combinations [12].

Only 52 of those 315 trials (16.5%) were classified as low risk of bias and sufficient to support efficacy. Of those 52, only 16 showed a significant between-group weight difference, and those differences ranged from 0.3 to 4.93 kg [12].

Sixteen out of 315. That is the base rate for this entire category. The authors concluded that dietary supplements and alternative therapies for weight loss have a limited high-quality evidence base, and The Obesity Society’s Clinical Committee urged clinicians to steer patients toward tested approaches instead [13]. An estimated 34% of Americans trying to lose weight have used one of these products.

What about GLP-1 patches?

These deserve their own section because they are the category’s clearest false-name product.

No FDA-approved transdermal GLP-1 product exists [14]. The patches sold on TikTok Shop, Amazon and standalone sites contain herbal ingredients such as berberine, green tea extract and chromium, not any GLP-1 receptor agonist [15].

There is also a physical problem. Intact skin blocks passive absorption of molecules much above roughly 500 daltons. Nicotine patches work because nicotine weighs about 162 daltons. Semaglutide weighs about 4,113 daltons. Even if a patch contained the drug, the skin would not let it through in any meaningful quantity [16].

No randomized controlled trial has shown that any over-the-counter weight-loss patch produces meaningful weight loss [15]. This is not new ground for regulators: in 2007 the FTC settled with Transdermal Products International Marketing Corporation and its owner William H. Newbauer for $180,000 and banned them from selling weight-loss patches, finding that advertising claims for the patches were false and unsubstantiated. The stipulated final order was entered in the Eastern District of Pennsylvania on July 24, 2007, and the FTC’s own headline on the matter was that products worn or rubbed on the skin do not cause weight loss [29].

Why is the FDA not stopping this?

Because under the Dietary Supplement Health and Education Act, supplements are regulated more like food than like drugs. Manufacturers do not need FDA approval before selling. Companies must tell the FDA that they hold evidence for structure-function claims, but as regulatory counsel at the Center for Science in the Public Interest has pointed out, they do not actually have to provide that evidence [17].

The enforcement gap is stark. Regulatory consultant Asa Waldstein of Supplement Advisory Group noted in 2025 that the FDA had issued only one warning letter to a supplement company over GLP-1-related claims: a December 10, 2024 letter to Veronvy over its “Elily Veronvy” and “Elily Veronvy 40+” products, which the agency treated as unapproved new drugs because they were intended to treat disease or affect the structure or function of the body [3]. The FDA confirmed the letter in its own December 17, 2024 roundup, describing Veronvy as offering “unapproved and misbranded oral GLP-1 products, including one that claims to be approved by FDA” [28]. Over roughly the same window, the FDA sent more than 40 warning letters in fall 2025, 30 in March 2026 and 25 in June 2026 to telehealth companies over compounded GLP-1 marketing.

The FTC is the other lever. It requires competent and reliable scientific evidence for health claims, has sent Notices of Penalty Offenses on substantiation to roughly 700 companies marketing supplements and functional foods, and maintains a separate Notice of Penalty Offenses covering weight-control promotion [18]. In past weight-loss settlements, the FTC has required two adequate and well-controlled human clinical studies before a company may make weight-loss claims. Almost nothing in the GLP-1 supplement category clears that bar.

There is also an important 2026 precedent from self-regulation. In the Tru Niagen matter, the National Advertising Review Board upheld the National Advertising Division’s recommendation that “clinically proven” claims be discontinued, and NAD adhered to FTC guidance that a product’s status as a dietary supplement “is a regulatory (FDA) matter, not as a consideration relevant to an assessment of whether a health claim is misleading or properly supported” [19]. In plain English: being a supplement does not lower the evidence bar for a health claim.

The Lemme lawsuits, and what they teach

The most instructive case in the category is Lemme GLP-1 Daily, from the wellness brand co-founded by Kourtney Kardashian Barker and Simon Huck.

The product’s central claim rests on an ingredient called Eriomin, a citrus bioflavonoid extract. Its supplier states Eriomin “consistently” demonstrated an average GLP-1 increase of about 17.5% versus placebo across three studies [20].

Here is the part that matters. According to the class action complaint and the Eriomin studies it cites, the ingredient did not demonstrate a decrease in body weight, BMI, waist-to-hip ratio or calorie intake [20]. Plaintiffs argue there is no clinical evidence that raising GLP-1 by 17% produces any effect on hunger, blood pressure, body weight or fat, and that the underlying studies were too small to support valid statistical conclusions [21]. The published crossover trial most often cited for the ingredient reported a 17% rise in GLP-1 alongside reductions in fasting glucose and inflammatory markers, and did not report weight loss as a finding [26]. The supplier has since announced a further study, as an adjunct to metformin, that it says found modest decreases in body weight, fat mass and BMI; that is a manufacturer announcement, and it does not change the point that the consumer-facing claim still rests on a hormone number rather than a weight outcome.

Where the litigation actually stands, which most coverage gets wrong. The same plaintiff, Christina Robins, filed two actions in early 2025: first in Los Angeles Superior Court on February 19, 2025 (No. 25STCV04635), alleging violations of California’s False Advertising Law, Unfair Competition Law and Consumer Legal Remedies Act, and then in the Southern District of New York on March 9, 2025 (Robins v. Lemme Inc., 1:25-cv-01938) [21][22]. The federal case did not proceed to a ruling on the merits. After Lemme moved to dismiss on April 8, 2025, the parties filed a stipulation of voluntary dismissal without prejudice under Rule 41(a)(1)(A)(ii), and the docket was terminated on April 16, 2025 [27]. “Without prejudice” means no court ever tested the claims and the case could in principle be refiled; it is not a finding that the advertising was accurate, and it is not a finding that it was not. Anyone citing these suits as proof of anything about the product is overreading them. The product, originally sold as Lemme GLP-1 Daily, has since been rebranded as Lemme Reset with the same formulation, and is sold through major retailers including Target and Walmart [22].

Whatever the legal outcome, the structure of the claim is the lesson, and it is independent of any court: a measurable biomarker change stands in for the outcome the consumer is actually buying.

What are the real safety risks?

Most of these products are probably inert, which is its own kind of problem. But four risks are real.

Drug interactions. Berberine is the main offender, through CYP2D6, CYP3A4 and CYP2C9 inhibition [7].

Stimulants. Fat-burner style products often contain bitter orange (synephrine) and caffeine. A 2022 systematic review concluded synephrine does not lack cardiovascular side effects and may not be a safe alternative to ephedrine for people with predisposing conditions. FDA laboratory work found that of 23 products making a synephrine label claim, only 22% were accurately labeled, and some contained synthetic amines including methylsynephrine at up to 240 mg per daily serving.

Undeclared drugs. An analysis of the FDA’s Health Fraud Product Database identified 1,068 unique supplement products marketed between 2007 and 2021 containing active pharmaceutical ingredients or substances deemed unsafe. Thirty-five percent were weight-loss products [23]. The most common adulterants are sibutramine, withdrawn from the US market in 2010 for raising heart attack and stroke risk, and phenolphthalein, removed from OTC laxatives in 1999. You cannot detect either by reading the label.

Label inaccuracy. ConsumerLab testing published in September 2023 found problems with nearly 45% of berberine and goldenseal supplements selected for testing, including two goldenseal products contaminated with lead [24].

So what, if anything, is worth buying?

If you are already on a GLP-1 drug and struggling with protein, fiber, constipation or micronutrients, the companion-nutrition category has a legitimate rationale and professional-society guidance behind it [4]. Buy those products for what they are, on their own terms, and ask your provider what actually applies to you.

If you are not on a GLP-1 and hoping a supplement will substitute for one, the evidence does not support that. Sixteen out of 315 trials is the honest headline, and the biggest ingredient effects in the category are one to three kilograms in the best case.

If cost is what pushed you here, price the approved options before you spend. Generic phentermine runs about $14 to $41 a month. Generic phentermine/topiramate ER, which produced roughly 10% weight loss in its trials, runs about $59 to $63 a month with a coupon. Foundayo and the Wegovy pill start around $149 a month self-pay. A GLP-1 booster capsule at $25 to $50 a month is not obviously the cheap option once you account for the fact that it does not work.

A nine-question checklist before you buy anything in this category

1. Does the product name contain a prescription drug name? That is either misbranding or deliberate confusion.
2. Is there a randomized, placebo-controlled trial of the finished product, not just its ingredients?
3. Does the milligram dose on the label match the dose in the cited study?
4. Is the cited outcome a biomarker, like a percentage rise in GLP-1, or actual weight loss?
5. Is there third-party testing (USP, NSF, ConsumerLab, Informed Choice)?
6. Does the product claim to treat obesity or diabetes? Disease claims make it an unapproved new drug under federal law.
7. Does it interact with your medications?
8. Is it sold on an auto-renewing subscription with a hard cancellation path? The FTC has acted on exactly this.
9. Would the money go further toward an approved drug?

This article summarizes what published studies, FDA-approved labeling and Instructions for Use, and regulatory records report. It is not medical advice, it does not recommend any product, drug or dose, and it is not a substitute for the labeling that comes with a product you have been prescribed. Follow your own prescription and the directions your prescriber and pharmacist give you, and talk to a healthcare provider before starting or stopping anything, including a supplement, especially if you take prescription medicines.

Sources

1. Straits Research — GLP-1 supplement market size (vendor estimate): https://straitsresearch.com/report/glp-1-supplement-market
2. Fact.MR — GLP-1 companion products market (vendor estimate): https://www.factmr.com/report/glp-1-companion-products-market
3. SupplySide Supplement Journal — Regulators mostly silent on GLP-1 supplement claims: https://www.supplysidesj.com/supplement-regulations/regulators-mostly-silent-on-glp-1-supplement-claims
4. Dietary supplement considerations during GLP-1 receptor agonist treatment: a narrative review: https://pmc.ncbi.nlm.nih.gov/articles/PMC12685510
5. Contemporary Clinic — GLP-1 boosters: responding to supplement marketing claims and safety questions: https://www.contemporaryclinic.com/view/glp-1-boosters-responding-to-supplement-marketing-claims-and-safety-questions
6. 2026 GLP-1 booster label comparison. Commercial source: this is a retailer blog that sells supplements; used only for the label ingredient lists it reproduces, not for any efficacy claim: https://yourhealthier.com/blogs/blog/best-supplements-for-glp-1-ozempic
7. Drugs.com — Berberine drug interactions: https://www.drugs.com/medical-answers/berberine-3569378
8. Chromium meta-analyses: Tsang C et al. 2019 (21 trials, n=1,316); Onakpoya I et al., Obes Rev 2013;14:496-507; Pittler MH et al. 2003. Commercial source used as a finding aid: the summary consulted sits on a supplement seller’s blog, and the underlying meta-analyses are the authority: https://drstanfield.com/blogs/articles/chromium-benefits-forms-dosing-and-side-effects
9. Depommier C et al., Nature Medicine 2019 — Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: https://pubmed.ncbi.nlm.nih.gov/31263284
10. Mount S et al., Nature Medicine, published May 12, 2026 — Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial (NCT05417360), doi 10.1038/s41591-026-04394-7. Manufacturer-funded: https://pubmed.ncbi.nlm.nih.gov/42120725
11. The positive effects of yerba maté in obesity (review): https://pmc.ncbi.nlm.nih.gov/articles/PMC4344557
12. Batsis JA et al., Obesity 2021 — A systematic review of dietary supplements and alternative therapies for weight loss: https://pubmed.ncbi.nlm.nih.gov/34159755
13. UNC Carolina Population Center / The Obesity Society — Review shows minimal high-quality evidence: https://www.cpc.unc.edu/news/review-shows-minimal-high-quality-evidence-dietary-supplements-lead-to-weight-loss
14. Ro — GLP-1 patches: do they work?: https://ro.co/weight-loss/glp-1-patches
15. Baptist Health — What are GLP-1 patches?: https://www.baptisthealth.com/blog/weight-management/what-are-glp-1-patches
16. Drugs.com — Do GLP-1 patches work?: https://www.drugs.com/medical-answers/glp-1-patches-work-fda-approval-proven-benefit-3582314
17. PBS NewsHour — In the gray world of GLP-1 supplements online, health experts urge caution: https://www.pbs.org/newshour/health/what-to-know-before-you-buy-a-weight-loss-supplement-on-tiktok
18. FTC — Notices of Penalty Offenses concerning weight loss: https://www.ftc.gov/enforcement/penalty-offenses/weightloss
19. SupplySide Supplement Journal — NAD/NARB uphold recommendations on “clinically proven” claims: https://www.supplysidesj.com/supplement-regulations/-clinically-proven-claims-are-out-national-advertising-division-recommendations-on-tru-niagen-upheld
20. SupplySide Supplement Journal — Class action targets Kardashian GLP-1 supplement: https://www.supplysidesj.com/litigation/class-action-targets-kardashian-glp-1-supplement
21. ClassAction.org — Lemme lawsuit claims GLP-1 weight loss capsules not as effective as advertised: https://www.classaction.org/news/lemme-lawsuit-claims-glp-1-weight-loss-capsules-not-as-effective-as-advertised
22. Global Cosmetics News — Lemme faces new class-action lawsuit over GLP-1 supplement marketing claims: https://www.globalcosmeticsnews.com/lemme-faces-new-class-action-lawsuit-over-glp-1-supplement-marketing-claims
23. FDA — Questions and answers about FDA’s initiative against contaminated weight loss products: https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/questions-and-answers-about-fdas-initiative-against-contaminated-weight-loss-products
24. ConsumerLab — Berberine and goldenseal supplements review: https://www.consumerlab.com/berberine
25. Science Media Centre — Expert reaction to an RCT on pasteurized Akkermansia muciniphila MucT for weight loss maintenance (May 12, 2026): https://www.sciencemediacentre.org/expert-reaction-to-an-rct-on-the-use-of-pasteurized-akkermansia-muciniphila-muct-for-weight-loss-maintenance-after-an-8-week-low-energy-diet
26. Ribeiro CB et al. — Nutraceutical eriocitrin (Eriomin) reduces hyperglycemia by increasing GLP-1 and downregulates systemic inflammation: a crossover randomized clinical trial: https://pmc.ncbi.nlm.nih.gov/articles/PMC9700344
27. Docket, Robins v. Lemme Inc., No. 1:25-cv-01938 (S.D.N.Y.) — stipulation of voluntary dismissal without prejudice under Rule 41(a)(1)(A)(ii); case terminated April 16, 2025: https://www.pacermonitor.com/public/case/57163217/Robins_v_Lemme_Inc
28. FDA — FDA Roundup: December 17, 2024 (confirms the Veronvy warning letter): https://www.fda.gov/news-events/press-announcements/fda-roundup-december-17-2024
29. FTC — Weight-Loss Patch Manufacturer Banned From Selling Weight-Loss Patches, Will Pay $180,000 (order entered E.D. Pa., July 24, 2007): https://www.ftc.gov/news-events/news/press-releases/2007/08/weight-loss-patch-manufacturer-banned-selling-weight-loss-patches-will-pay-180000
30. Wilding JPH et al., N Engl J Med 2021;384(11):989-1002 — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NCT03548935): https://pubmed.ncbi.nlm.nih.gov/33567185